Human Immunology Biosciences (HI-Bio)
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $95M
Overview
Developing targeted therapies to deplete pathogenic immune cells in severe immune-mediated and rare diseases.
ImmunologyRare Disease
Technology Platform
A targeted immunology platform focused on developing monoclonal antibodies that selectively deplete specific pathogenic immune cell populations, such as plasma cells and effector B cells.
Funding History
1Total raised:$95M
Series B$95M
Opportunities
Potential to establish a new precision medicine paradigm in nephrology and other antibody-driven diseases with high unmet need.
Risk Factors
Clinical efficacy may be disease-specific, and commercial success depends on penetrating specialized markets dominated by standard-of-care therapies.
Competitive Landscape
Faces competition from other biotechs and large pharma in the nephrology and transplant rejection spaces, requiring clear efficacy advantages in specific patient populations.